Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study

Al-Sukhni W, Borgida A, Rothenmund H, Holter S, Semotiuk K, Grant R, et al. Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg. 2012;16(4):771–83. https://doi.org/10.1007/s11605-011-1781-6.

Article  Google Scholar 

Al-Sukhni W, Aronson M, Gallinger S. Hereditary colorectal cancer syndromes: familial adenomatous polyposis and lynch syndrome. Surg Clin North Am. 2008;88(4):819–44. https://doi.org/10.1016/j.suc.2008.04.012.

Article  Google Scholar 

American Cancer Society. Key statistics for pancreatic cancer. [American Cancer Sociaty About pancreatic Cancer website]. http://www.cancer.org/cancer/pancreatic-cancer/about/key-statistics.html. Accessed 4 Sep 2018.

Astiazaran-Symonds E, Goldstein AM. A systematic review of the prevalence of germline pathogenic variants in patients with pancreatic cancer. J Gastroenterol. 2021;56(8):713–21. https://doi.org/10.1007/s00535-021-01806-y.

Article  Google Scholar 

Barbari SR, Shcherbakova PV. Replicative DNA polymerase defects in human cancers: consequences, mechanisms, and implications for therapy. DNA Repair. 2017;56:16–25. https://doi.org/10.1016/j.dnarep.2017.06.003.

Article  CAS  Google Scholar 

Berek JS, Chalas E, Edelson M, Moore DH, Burke WM, Cliby WA, et al. Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol. 2010;116(3):733–43. https://doi.org/10.1097/AOG.0b013e3181ec5fc1.

Article  Google Scholar 

Buchanan DD, Stewart JR, Clendenning M, Rosty C, Mahmood K, Pope BJ, et al. Risk of colorectal cancer for carriers of a germ-line mutation in POLE or POLD1. Genet Med. 2018;20(8):890–5. https://doi.org/10.1038/gim.2017.185.

Article  CAS  Google Scholar 

Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62(3):339–47. https://doi.org/10.1136/gutjnl-2012-303108. Hammell, Pascal [corrected to Hammel, Pascal]. Erratum in: Gut. 2014;63(1):178.

Article  Google Scholar 

Cazacu IM, Farkas N, Garami A, Balaskó M, Mosdósi B, Alizadeh H, et al. Pancreatitis-associated genes and pancreatic cancer risk: a systematic review and meta-analysis. Pancreas. 2018;47(9):1078–86. https://doi.org/10.1097/MPA.0000000000001145.

Article  CAS  Google Scholar 

Couch FJ, Johnson MR, Rabe K, Boardman L, McWilliams R, de Andrade M, et al. Germline Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res. 2005;65(2):383–6.

Article  CAS  Google Scholar 

Couch FJ, Johnson MR, Rabe KG, Brune K, de Andrade M, Goggins M, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(2):342–6. https://doi.org/10.1158/1055-9965.

Article  CAS  Google Scholar 

Cremin C, Lee MK, Hong Q, Hoeschen C, Mackenzie A, Dixon K, et al. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening. Cancer Med. 2020;9(11):4004–13. https://doi.org/10.1002/cam4.2973.

Article  CAS  Google Scholar 

Cybulski C, Górski B, Huzarski T, Masojć B, Mierzejewski M, Debniak T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004;75(6):1131–5. https://doi.org/10.1086/426403.

Article  CAS  Google Scholar 

Durno C, Corey M, Zielenski J, Tullis E, Tsui LC, Durie P. Genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis. Gastroenterology. 2002;123(6):1857–64. https://doi.org/10.1053/gast.2002.37042.

Article  Google Scholar 

Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, et al. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res. 2011;31(4):1417–20.

Google Scholar 

Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020;69(1):7–17. https://doi.org/10.1136/gutjnl-2019-319352. Erratum. In: Gut. 2020;69(6):e3.

Article  CAS  Google Scholar 

Grant RC, Selander I, Connor AA, Selvarajah S, Borgida A, Briollais L, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology. 2015;148(3):556–64. https://doi.org/10.1053/j.gastro.2014.11.042.

Article  CAS  Google Scholar 

Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93(21):1633–7. https://doi.org/10.1093/jnci/93.21.1633.

Article  CAS  Google Scholar 

Holter S, Borgida A, Dodd A, Grant R, Semotiuk K, Hedley D, et al. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. J Clin Oncol. 2015;33(28):3124–9. https://doi.org/10.1200/JCO.2014.59.7401.

Article  CAS  Google Scholar 

Hu C, Hart SN, Bamlet WR, Moore RM, Nandakumar K, Eckloff BW, et al. Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients. Cancer Epidemiol Biomarkers Prev. 2016;25(1):207–11. https://doi.org/10.1158/1055-9965.EPI-15-0455.

Article  CAS  Google Scholar 

Hu C, Hart SN, Polley EC, Gnanaolivu R, Shimelis H, Lee KY, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA. 2018;319(23):2401–9. https://doi.org/10.1001/jama.2018.6228.

Article  CAS  Google Scholar 

Johns AL, McKay SH, Humphris JL, Pinese M, Chantrill LA, Mead RS, et al. Lost in translation: returning germline genetic results in genome-scale cancer research. Genome Med. 2017;9(1):41. https://doi.org/10.1186/s13073-017-0430-4.

Article  Google Scholar 

Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801–6. https://doi.org/10.1126/science.1164368.

Article  CAS  Google Scholar 

Klein AP, Hruban RH, Brune KA, Petersen GM, Goggins M. Familial pancreatic cancer. Cancer J. 2001;7(4):266–73.

CAS  Google Scholar 

Klein AP. Genetic susceptibility to pancreatic cancer. Mol Carcinog. 2012;51(1):14–24. https://doi.org/10.1002/mc.2085.

Article  CAS  Google Scholar 

Lee JH, Kim Y, Choi JW, Kim JS. KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. Springer plus. 2016;5(1):1172. https://doi.org/10.1186/s40064-016-2847-4.

Article  CAS  Google Scholar 

Li Z, Shao C, Liu X, Lu X, Jia X, Zheng X, et al. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. Carcinogenesis. 2020;41(1):44–55. https://doi.org/10.1093/carcin/bgz086.

Article  CAS  Google Scholar 

Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20:197–209. https://doi.org/10.1016/j.bpg.2005.10.001.

Article  Google Scholar 

Magrin L, Fanale D, Brando C, Fiorino A, Corsini LR, Sciacchitano R, et al. POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes. Oncogene. 2021;40(40):5893–901. https://doi.org/10.1038/s41388-021-01984-2.

Article  CAS  Google Scholar 

Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA. 2017;318(9):825–35. https://doi.org/10.1001/jama.2017.11137. Erratum. In: JAMA. 2018;320(22):2381.

Article  Google Scholar 

Matsubayashi H, Fukushima N, Sato N, Brune K, Canto M, Yeo CJ, et al. Polymorphisms of SPINK1 N34S and CFTR in patients with sporadic and familial pancreatic cancer. Cancer Biol Ther. 2003;2(6):652–5.

Article  CAS  Google Scholar 

McWilliams R, Highsmith WE, Rabe KG, de Andrade M, Tordsen LA, Holtegaard LM, et al. Cystic fibrosis transmembrane regulator gene carrier status is a risk factor for young onset pancreatic adenocarcinoma. Gut. 2005;54(11):1661–2. https://doi.org/10.1136/gut.2005.074534.

Article  CAS  Google Scholar 

McWilliams RR, Petersen GM, Rabeb KG, Holtegaard LM, Lynch PJ, Bishop MD, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma. Cancer. 2010;116(1):203–9. https://doi.org/10.1002/cncr.24697.

Article  CAS  Google Scholar 

Moghadasi S, Eccles DM, Devilee P, Vreeswijk MP, van Asperen CJ. Classification and clinical management of variants of uncertain significance in high penetrance cancer predisposition genes. Hum Mutat. 2016;37(4):331–6. https://doi.org/10.1002/humu.22956.

Article  CAS  Google Scholar 

Mur P, García-Mulero S, Del Valle J, Magraner-Pardo L, Vidal A, Pineda M, et al. Role of POLE and POLD1 in familial cancer. Genet Med. 2020;22(12):2089–100. https://doi.org/10.1038/s41436-020-0922-2.

Article  CAS  Google Scholar 

Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29(11):1282–91. https://doi.org/10.1002/humu.20880.

Article  CAS  Google Scholar 

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24. https://doi.org/10.1038/gim.2015.30.

Article  Google Scholar 

Rittenhouse DW, Talbott VA, Anklesaria Z, Brody JR, Witkiewicz AK, Yeo CJ. Subject review: pancreatic ductal adenocarcinoma in the setting of mutations in the cystic fibrosis transmembrane conductance regulator gene: case report and review of the literature. J Gastrointest Surg. 2011;15(12):2284–90. https://doi.org/10.1007/s11605-011-1639-y.

Article  Google Scholar 

Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2012;2(1):41–6. https://doi.org/10.1158/2159-8290.CD-11-0194.

Article  CAS  Google Scholar 

Roberts NJ, Norris AL, Petersen GM, Bondy ML, Brand R, Gallinger S, et al. Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov. 2016;6(2):166–75. https://doi.org/10.1158/2159-8290.CD-15-0402.

Article  CAS  Google Scholar 

Roch AM, Schneider J, Carr RA, Lancaster WP, House MG, Zyromski NJ, et al. Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma? J Surg Oncol. 2019;119(6):777–83. https://doi.org/10.1002/jso.25376.

Article  CAS  Google Scholar 

Shindo K, Yu J, Suenaga M, Fesharakizadeh S, Cho C, Macgregor-Das A, et al. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J Clin Oncol. 2017;35(30):3382–90. https://doi.org/10.1200/JCO.2017.72.3502.

Article  CAS 

留言 (0)

沒有登入
gif